Novacta Therapeutics

Novacta Therapeutics is a UK-based biotechnology company specializing in the development of novel antibiotics derived from lantibiotics. The company utilizes a proprietary chemistry and fermentation platform to engineer naturally occurring peptides into potent anti-infective agents. Its lead program, NVB302, is a semi-synthetic derivative of the lantibiotic actagardine, specifically developed to treat Clostridium difficile infections while sparing the healthy gut flora. Novacta's research focus addresses the growing global threat of antibiotic resistance by targeting essential bacterial components like Lipid II. The company was acquired by Alizé Pharma II in 2017 to further the development of its anti-infective portfolio.